Paycom Still Trades Growth Fatigue, Not a 31% Board Bid

Summary: PAYC last traded at $136.24 on May 16, 2026 at 06:15 Ho Chi Minh City time. Paycom repurchased 8,375,443 shares for $1.060 billion in the first quarter, cutting shares outstanding from 54.8 million at December 31, 2025 to 46.6 million at March 31, 2026. As of April 28, 2026, the company disclosed 47,631,450 shares outstanding. Against that count, the new $2.0 billion repurchase authorization approved on May 4, 2026 is equivalent to about 14.7 million shares, or roughly 30.8% of the current share count at today's price by my calculation. The market still seems to value Paycom like a mature HCM vendor with AI and labor-cycle risk, not like a company whose own board is trying to retire nearly a third of the stock while reiterating $2.175 billion to $2.195 billion of 2026 revenue and $950 million to $970 million of adjusted EBITDA guidance. [1][2][3][4]

Opportunity Ranking

Rank	Idea	Discovery Lane	Why It May Be Best Now	Evidence Freshness	Catalyst Window	Asymmetry	Main Reason to Reject
1	Paycom still trades growth fatigue, not a 31% board bid	U.S. mid-cap HCM software / capital return / share-count compression	Paycom already retired 8.38 million shares in Q1 and then approved a fresh $2.0 billion authorization that equals about 30.8% of the current share count at today's price by my calculation, while keeping 2026 revenue and adjusted EBITDA guidance intact.	Live `PAYC` price checked May 16, 2026; official Q1 release and 10-Q filed May 6-7, 2026.	Ongoing repurchases, the next quarterly filing, and evidence that recurring revenue and margins still hold.	The board has already shown it is willing to buy size, not just authorize it.	The buyback is partly debt-funded, so a real slowdown could make the whole setup look like financial engineering.
2	Zealand Pharma buys back stock while the obesity optionality is still doing the valuation work	Europe / Denmark biotech / cash-backed buyback	Zealand launched a DKK 1.3 billion buyback with a stated USD 2.3 billion cash position after positive obesity-program developments.	Official buyback release dated May 7, 2026; public quote reference checked May 8, 2026.	Buyback runs through October 31, 2026 plus ongoing obesity-program updates.	Cash support is real and public.	The valuation still lives and dies by pipeline probability, not by the buyback alone.
3	Murata's largest-ever buyback still sits inside hardware-cycle skepticism	Japan large-cap electronics / buyback / cancellation	Murata approved its largest-ever buyback at JPY 150 billion and plans to cancel 75 million shares while still investing for data-center demand.	Official Murata notice dated April 30, 2026; public quote reference updated May 13, 2026.	Repurchases run through January 29, 2027 and cancellation is scheduled for February 26, 2027.	Clean capital-return mechanics in a liquid name.	The market may keep pricing the component cycle and capex more than the share count.
4	BCA begins buybacks while deposits and profit still compound	Broader Asia / Indonesia bank / capital return	BCA started executing a buyback on April 28, 2026 after reporting Rp14.7 trillion of Q1 net profit, 5.6% loan growth, and 11.2% CASA growth.	Official Q1 performance and buyback releases dated April 24 and April 29, 2026; public quote reference checked May 13, 2026.	Twelve-month buyback window and the next quarterly banking print.	The franchise quality is obvious and the balance sheet remains strong.	The buyback is less mechanically forceful than the selected setup, and local macro plus FX can keep the discount open.

Geographic Search Audit

U.S. candidate screened: Paycom.
Japan candidate screened: Murata Manufacturing.
Broader Asia candidate screened: BCA.
Europe / UK candidate screened: Zealand Pharma.
Why Paycom won: it has the freshest and most mechanical per-share setup, the cleanest public evidence that the board is already buying size, and the most tradeable closing path without having to underwrite a biotech or macro branch first.

Why This Is the Best Opportunity Right Now

The best current setup is the one where the market and the board are making visibly different bets with real money.

That is Paycom.

Paycom did not just announce a buyback. It already retired 8,375,443 shares in one quarter for $1.060 billion, taking outstanding shares from 54.8 million at year-end 2025 to 46.6 million at March 31, 2026. Then, on May 4, 2026, the board approved a fresh $2.0 billion authorization and, by April 28, 2026, the company still had only 47,631,450 shares outstanding. At the current $136.24 stock price, that new authorization covers about 14.7 million shares, or roughly 30.8% of the current share count by my calculation. [1][2][4]

The market does not need to believe Paycom is becoming a hyper-growth software name again for that math to matter.

It only needs to believe the business is stable enough that the board is not setting money on fire.

What Should Surprise the Reader

The surprise is not that Paycom is buying stock.

The surprise is the scale.

One quarter already removed roughly 15.0% of the prior year-end share count. The fresh authorization is still big enough to cover about 30.8% of the current count at today's price. Yet the stock sits only about 7.6% above the company's own average first-quarter repurchase price of roughly $126.56 by my calculation. [1][2][4]

That is not normal background capital return. That is management making an explicit, aggressive statement about where it thinks the public market is wrong.

The Setup

Paycom is no longer priced as a fast, scarce software compounder. The tape now treats it more like a maturing payroll and HCM vendor whose growth is good enough to survive but not good enough to deserve a premium.

That skepticism is not invented. The 2026 guide implies only 6% to 7% total revenue growth and 7% to 8% recurring-revenue growth. The company also used borrowings under its revolving credit facility to fund part of the first-quarter repurchase. [1][2][3]

But that is exactly why the setup matters. If the business were obviously pristine, the board would not be getting the chance to retire this much stock at this multiple.

The Mispricing

Fact: First-quarter 2026 revenue was $571.9 million, up 7.8% year over year, with recurring and other revenue up 8.8% to $544.0 million. [1]

Fact: First-quarter adjusted EBITDA was $275.4 million, or 48.2% of revenue. [1]

Fact: Management reiterated 2026 guidance for $2.175 billion to $2.195 billion of revenue and $950 million to $970 million of adjusted EBITDA. [1]

Fact: Shares outstanding fell from 54.8 million at December 31, 2025 to 46.6 million at March 31, 2026 after the company repurchased 8,375,443 shares for $1.060 billion in the quarter. [1][2]

Fact: Paycom had $153.9 million of cash and cash equivalents at quarter-end and $675.0 million outstanding under its revolving credit facility. [1][2]

Fact: On April 23, 2026, Paycom amended and upsized the revolving credit facility to $2.125 billion, with permitted uses including share repurchases. [3]

Inference: The market still prices Paycom primarily as a slower-growth HCM vendor with AI-disruption and labor-market sensitivity, while management is pricing it as a company whose per-share value can compound materially through aggressive share shrink even if operating growth stays merely decent.

That gap is the file.

Price

Metric	Reading	Why It Matters
`PAYC` last price	$136.24	Current public-market entry reference
Q1 revenue	$571.9 million	The business is still growing, even if not at old software multiples
Q1 recurring and other revenue	$544.0 million	Recurring revenue remains the core engine
Q1 adjusted EBITDA	$275.4 million	Margin quality is still high
2026 revenue guide	$2.175 billion to $2.195 billion	The company did not cut while buying size
2026 adjusted EBITDA guide	$950 million to $970 million	Midpoint implies a still-strong earnings engine
Shares outstanding at Dec. 31, 2025	54.8 million	Starting denominator before the Q1 shrink
Shares outstanding at Mar. 31, 2026	46.6 million	Q1 alone removed about 15.0% of the prior count
Shares outstanding at Apr. 28, 2026	47,631,450	Best current public share-count anchor from the 10-Q
Q1 shares repurchased	8,375,443	The board already executed size
Q1 repurchase spend	$1.060 billion	The buyback is not hypothetical
Average Q1 repurchase price	about $126.56 by my calculation	The stock is only modestly above the board's own recent bid
New repurchase authorization	$2.0 billion	Equal to about 14.7 million shares, or 30.8% of the current count, at today's price by my calculation
Cash and cash equivalents	$153.9 million	Buyback capacity is not just idle cash
Long-term debt	$675.0 million	Leverage is real and part of the risk
Enterprise value / 2026E adjusted EBITDA	about 7.3x by my calculation	Low for a sticky HCM model if the guide holds

PAYC last traded at $136.24 on May 16, 2026 at 06:15 Ho Chi Minh City time. [4]

Positioning

I did not verify fresh securities-lending data, current short-interest files, or a live options-open-interest map strong enough to claim a squeeze.

The positioning evidence here is corporate, not speculative.

Management itself is the visible buyer. The verified share-count reduction is already large enough that the main flow question is no longer whether the board means it. It is whether the business remains stable enough for the board to keep going.

The market-side positioning claim is an inference: Paycom still seems to trade inside a low-growth, AI-disruption, labor-sensitive narrative. That inference fits the valuation and management's willingness to use leverage to repurchase stock, but it is still an inference, not a directly verified crowding file.

Catalyst

The closing path is practical.

First, future quarterly filings will show whether Paycom continues to shrink the denominator after already taking it down sharply in Q1. [1][2]

Second, the next operating print has a simple burden of proof. Recurring revenue needs to remain in the guided zone and adjusted EBITDA needs to stay near the $950 million to $970 million annual range. The thesis does not require a reacceleration. It requires stability. [1]

Third, the new $2.125 billion revolving facility makes the capital-allocation choice observable rather than theoretical. If management keeps using that balance-sheet flexibility for repurchases without damaging the operating profile, the per-share math gets harder for the market to ignore. [3]

Payoff Map

The cleanest expression is long PAYC common stock.

This is not an options-first setup. I did not verify a live options chain with enough confidence to underwrite strikes, implied volatility, or expiration-specific liquidity. The thesis does not need synthetic leverage. It needs the operating guide to hold and the share count to keep falling.

Price Target and Probability Map

Scenario	Probability	Target / Level	Return / Payoff	Time Horizon	Conditions Required	Evidence Quality
Top Case	30%	$162.00	+18.9%	3 to 9 months	Management continues to execute the repurchase plan, recurring revenue stays intact, and the market pays a modestly higher multiple for a shrinking-share software cash flow stream.	Medium
Base Case	45%	$150.00	+10.1%	3 to 9 months	The business simply holds the current guide, leverage remains controlled, and the market gives partial credit to the already visible denominator shrink.	Medium
Bottom Case	25%	$120.00	-11.9%	1 to 6 months	Growth slows, the labor backdrop weakens, rates on client funds become less helpful, or the board becomes more cautious because the leverage optics worsen.	Medium
Invalidation / Stop Condition	n/a	Sustained break below $120.00 or clear evidence that buybacks are being rationed because operating or leverage pressure is worsening	Thesis broken	Immediate once visible	If the business no longer looks stable enough to support the capital-return strategy, the edge is gone.	High

Probability-weighted expected value: $146.10, or about +7.2% versus the current stock price. Current market price / level: PAYC $136.24 Timestamp: OpenAI finance snapshot, May 16, 2026 at 06:15 Ho Chi Minh City time Primary instrument: PAYC common stock Alternative expressions considered: waiting for the next quarterly filing to confirm another leg down in share count; options only after live chain verification; no-trade if repurchase execution slows materially Confidence: Medium

What Would Prove This Wrong

This thesis fails if the buyback is the story because the business no longer is.

The clearest falsifiers are:

recurring-revenue growth slipping below the current guided range,
adjusted EBITDA or free cash flow weakening enough to make the debt-funded repurchase look defensive rather than opportunistic,
a visible slowdown in share-count reduction despite the expanded facility and authorization, or
a market conclusion that interest on client funds flattered the quarter more than the core product deserved.

If those conditions emerge, the market is not underpricing Paycom. It is correctly refusing to capitalize buyback math on top of a deteriorating operating base.

Risk Audit

The strongest counterargument is that the market is not missing anything. It is simply refusing to reward a mid-single-digit grower that just levered up to buy back stock.

That is a serious argument.

Cash and cash equivalents fell to $153.9 million at quarter-end, while long-term debt rose to $675.0 million. Management clearly believes the stock is cheap, but management also controls the choice to use leverage. If organic growth slips, that decision can look less like discipline and more like financial engineering. [1][2][3]

There is also a subtler risk. Paycom still benefits from interest on funds held for clients, and that line is worth about $103 million in the current 2026 revenue guide. If rate help fades or client-fund balances soften, per-share math alone may not be enough to close the gap. [1]

Bottom Line

Paycom does not need a heroic growth rebound for this setup to work. It needs operating stability and continued board aggression. At $136.24, after already shrinking the share count about 15.0% in one quarter, the company still has a fresh $2.0 billion authorization that covers about 30.8% of the current share count at today's price by my calculation. The market still seems to price growth fatigue first and share-count math second. That ordering may be wrong.

Research Quality Scorecard

The full scorecard is kept in the companion meta file.

Sources

Best Trade Strategy

Best trade: Long PAYC common stock.